Mast Therapeutics (MSTX) Reports In-Line Q2 EPS
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- S&P 500 inches lower as Middle East tensions outweigh tech gains
- L3Harris CEO steps down amid conduct review, shares drop
- Reddit leads social media platforms in revenue growth per user
- Northland Upgrades Astera Labs (ALAB) to Outperform, 'Right Time, Customers, and Products'
- H.C. Wainwright Reiterates Buy Rating on Soluna (SLNH)
Mast Therapeutics Reports Second Quarter 2015 Financial Results
August 12, 2015 4:05 PM EDTSAN DIEGO, Aug. 12, 2015 /PRNewswire/ --Â Mast Therapeutics, Inc. (NYSE MKT: MSTX), a clinical-stage biopharmaceutical company leveraging its molecular adhesion and sealant technology (MAST) platform to develop novel therapies for sickle cell disease, arterial disease and heart failure, today reported financial results for the quarter ended June 30, 2015.
"Our biggest priority in the second quarter of 2015 was continuing the enthusiasm and momentum for enrollment in EPIC, our Phase 3 trial of vepoloxamer, and we are pleased to... More
